# US 2025/0152693 A1 · Neisseria Meningitidis Vaccine

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0152693 A1
- Document ID: US20250152693A1
- Status: Published application
- Kind: A1
- Application number: 19/022,412
- Filed: 2025-01-15
- Published: 2025-05-15
- Earliest claimed: 2016-09-02
- Assignees: Sanofi Pasteur Limited
- Applicants: Sanofi Pasteur Inc.
- Inventors: Richard David Kensinger, JR.; Steven L. Hauser
- Web page: https://patentgrep.com/patent/US20250152693A1

## CPC

- A61K 39/095: Neisseria
- A61K 47/18: Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K 47/36: Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K 47/6415: {Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins}
- A61K 47/65: Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
- A61P 31/04: Antibacterial agents
- A61P 37/04: Immunostimulants
- A61K 2039/55583: {Polysaccharides}
- A61K 2039/6037: {Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]}
- A61K 2039/70: {Multivalent vaccine}
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Provided herein are compounds, compositions, formulations, kits, uses, and methods for vaccinating a subject against Neisseria meningitidis.

## Claims

### Claim 1

A Neisseria meningitidis vaccine composition comprising:
a) a first conjugate of MenA capsular polysaccharide to a carrier protein;
b) a second conjugate of MenC capsular polysaccharide to a carrier protein;
c) a third conjugate of MenW-135 capsular polysaccharide to a carrier protein; and
d) a fourth conjugate of MenY capsular polysaccharide to a carrier protein;
wherein the second conjugate is a population comprising double-end-linked conjugated polysaccharides and single-end-linked conjugated polysaccharides which both are attached to the carrier protein through a secondary amine, and the polysaccharides of the second conjugate have an O-acetylation level of 0.3 μmol/mg polysaccharide to 1.6 μmol/mg polysaccharide.

### Claim 2

A Neisseria meningitidis vaccine composition comprising:
a) a first conjugate of MenA capsular polysaccharide to a carrier protein;
b) a second conjugate of MenC capsular polysaccharide to a carrier protein;
c) a third conjugate of MenW-135 capsular polysaccharide to a carrier protein; and
d) a fourth conjugate of MenY capsular polysaccharide to a carrier protein;
wherein the second conjugate is a population comprising single-end-linked conjugated polysaccharides which are attached to the carrier protein through a secondary amine, wherein the single-end-linked conjugated polysaccharides have a terminal unlinked saccharide, wherein the terminal saccharide has a primary hydroxyl or secondary amine linkage at the 7 position, or wherein the reducing end is modified with a (2-hydroxy)ethoxy or secondary amine linkage.

### Claim 3

A Neisseria meningitidis vaccine composition comprising:
a) a first conjugate of MenA capsular polysaccharide to a carrier protein;
b) a second conjugate of MenC capsular polysaccharide to a carrier protein;
c) a third conjugate of MenW-135 capsular polysaccharide to a carrier protein; and
d) a fourth conjugate of MenY capsular polysaccharide to a carrier protein;
wherein the MenA capsular polysaccharide is attached to the carrier protein through a linker comprising a carbamate, a spacer, and an amide, wherein the spacer is between the carbamate and the amide and comprises 2-10 linear carbons, and the first conjugate has a polysaccharide to carrier protein mass ratio of 0.3 to 1.5.

### Claim 4

A Neisseria meningitidis vaccine composition comprising:
a) a first conjugate of MenA capsular polysaccharide to a carrier protein;
b) a second conjugate of MenC capsular polysaccharide to a carrier protein;
c) a third conjugate of MenW-135 capsular polysaccharide to a carrier protein; and
d) a fourth conjugate of MenY capsular polysaccharide to a carrier protein;
wherein the MenA capsular polysaccharide is attached to the carrier protein through a linker comprising a carbamate, a spacer, and an amide, wherein the spacer is between the carbamate and the amide and comprises 2-10 linear carbons; and wherein the MenC, MenW-135, and MenY capsular polysaccharides are attached to the carrier protein through a secondary amine; and
at least one of the conjugates has a weight average molecular weight ranging from 300 kDa to 1500 kDa.

### Claim 5

A Neisseria meningitidis vaccine composition comprising:
a) a first conjugate of MenA capsular polysaccharide to a carrier protein;
b) a second conjugate of MenC capsular polysaccharide to a carrier protein;
c) a third conjugate of MenW-135 capsular polysaccharide to a carrier protein; and
d) a fourth conjugate of MenY capsular polysaccharide to a carrier protein;
wherein the carrier protein is tetanus toxoid;
one or more of the first, second, third, and fourth conjugates has a weight average molecular weight ranging from 300 kDa to 1500 kDa; and the composition comprises less than 20% free polysaccharide by weight relative to total polysaccharide.

### Claim 6

A Neisseria meningitidis vaccine composition comprising:
a) a first conjugate of MenA capsular polysaccharide to a carrier protein;
b) a second conjugate of MenC capsular polysaccharide to a carrier protein;
c) a third conjugate of MenW-135 capsular polysaccharide to a carrier protein; and
d) a fourth conjugate of MenY capsular polysaccharide to a carrier protein;
wherein the carrier protein is tetanus toxoid;
one or more of the first, second, third, and fourth conjugates have a polysaccharide to carrier protein mass ratio of 0.3 to 1.5; and the composition comprises less than 20% free polysaccharide by weight relative to total polysaccharide.

### Claim 7

The vaccine composition of any one of the preceding claims, wherein the first, second, third, and/or fourth conjugates are a population comprising molecules with a molecular weight in the range of 700 kDa to 1400 kDa or 800 kDa to 1300 kDa.

### Claim 8

A Neisseria meningitidis vaccine composition comprising a conjugate of MenC capsular polysaccharide to a carrier protein, wherein the conjugate is a population comprising double-end-linked conjugated polysaccharides and single-end-linked conjugated polysaccharides which both are attached to the carrier protein through a secondary amine, and the polysaccharides of the conjugate of MenC capsular polysaccharide to the carrier protein have an O-acetylation level ranging from 0.3 μmol/mg polysaccharide to 1.6 μmol/mg polysaccharide.

### Claim 9 (depends on 8)

The vaccine composition of claim 8, wherein the conjugate
(a) has a weight average molecular weight ranging from 300 kDa to 1500 kDa; or
(b) is a population comprising molecules having a molecular weight in the range of 700 kDa to 1400 kDa or 800 kDa to 1300 kDa.

### Claim 10 (depends on 4, 5, 7)

The vaccine composition of any one of claims 4, 5, 7, or 9, wherein molecular weight is determined by multi-angle light scattering (MALS).

### Claim 11

The vaccine composition of any one of the preceding claims, wherein the MenC polysaccharide has a degree of O-acetylation ranging from 0.6 to 1.5 μmol/mg polysaccharide or 0.8 to 1.4 μmol/mg polysaccharide.

### Claim 12 (depends on 11)

The vaccine composition of claim 11, wherein the degree of O-acetylation is greater than or equal to 0.7, 0.8, 0.9, 1.0, 1.1, or 1.2 μmol/mg polysaccharide.

### Claim 13 (depends on 11)

The vaccine composition of claim 11, wherein the degree of O-acetylation is less than or equal to 0.8, 0.9, 1.0, 1.1, 1.2, 1.3, or 1.4 μmol/mg polysaccharide.

### Claim 14

The vaccine composition of any one of the preceding claims, wherein the conjugate comprising MenC polysaccharide is a population comprising double-end-linked conjugated polysaccharides and single-end-linked conjugated polysaccharides.

### Claim 15 (depends on 14)

The vaccine composition of claim 14, wherein the single-end-linked polysaccharides of the second conjugate comprise a terminal unlinked saccharide, wherein the single-end-linked conjugated polysaccharides have a terminal unlinked saccharide, wherein the terminal saccharide has a primary hydroxyl at the 7 position, or wherein the reducing end is modified with a (2-hydroxy)ethoxy.

### Claim 16

The vaccine composition of any one of the preceding claims, wherein the conjugate comprising MenC polysaccharide comprises one or more modifications chosen from (i) a primary hydroxyl at the 7 position, (ii) a (2-hydroxy)ethoxy at the reducing end, and (iii) a conjugation to the carrier protein, wherein the modifications are present at no less than 25 nmol/mg polysaccharide.

### Claim 17

The vaccine composition of any one of the preceding claims, comprising a conjugate of MenW-135 and/or MenY polysaccharide which comprises one or more modifications chosen from (i) a primary hydroxyl at a position of a vicinal diol in a native MenW-135 or MenY polysaccharide and (ii) a conjugation to the carrier protein, wherein the modifications are present at no less than 60 nmol/mg polysaccharide.

### Claim 18 (depends on 16, 17)

The vaccine composition of claim 16 or 17, wherein the modifications are present in an amount less than 200 nmol/mg polysaccharide, less than 150 nmol/mg polysaccharide, less than 150 nmol/mg polysaccharide, less than 100 nmol/mg polysaccharide, or less than 80 nmol/mg polysaccharide.

### Claim 19

The vaccine composition of any one of the preceding claims, wherein the MenC polysaccharide is reduced in size by 3×-8× relative to native MenC polysaccharide.

### Claim 20

The vaccine composition of any one of the preceding claims, comprising a conjugate of MenA capsular polysaccharide to a carrier protein having a polysaccharide to carrier protein mass ratio of 0.5 to 1.5 or 0.7 to 1.4.

### Claim 21 (depends on 20)

The vaccine composition of claim 20, wherein the MenA conjugate has a polysaccharide to carrier protein mass ratio of 0.8 to 1.3.

### Claim 22

The vaccine composition of any one of the preceding claims, comprising a conjugate of MenC and/or MenY capsular polysaccharide to a carrier protein having a polysaccharide to carrier protein mass ratio of 0.3 to 1.1.

### Claim 23 (depends on 22)

The vaccine composition of claim 22, wherein the MenC conjugate has a polysaccharide to carrier protein mass ratio of 0.4 to 0.8.

### Claim 24

The vaccine composition of any one of the preceding claims, comprising a conjugate of MenW-135 capsular polysaccharide to a carrier protein having a polysaccharide to carrier protein mass ratio of 0.3 to 1.3.

### Claim 25 (depends on 24)

The vaccine composition of claim 24, wherein the MenW-135 conjugate has a polysaccharide to carrier protein mass ratio of 0.6 to 1.3.

### Claim 26

The vaccine composition any one of the preceding claims, comprising a conjugate of MenY capsular polysaccharide to a carrier protein having a polysaccharide to carrier protein mass ratio of 0.5 to 1.3.

### Claim 27 (depends on 26)

The vaccine composition of claim 26, wherein the MenY conjugate has a polysaccharide to carrier protein mass ratio of 0.5 to 0.9.

### Claim 28

The vaccine composition of any one of the preceding claims, wherein the composition comprises less than 20% free polysaccharide by weight.

### Claim 29 (depends on 28)

The vaccine composition of claim 28, wherein the composition comprises less than 10% free polysaccharide by weight, less than 5% free polysaccharide by weight, or substantially lacks free polysaccharide.

### Claim 30

The vaccine composition of any one of the preceding claims, wherein the polysaccharide of the MenA, MenC, MenW-135, or MenY conjugate is attached to the carrier protein through a linker.

### Claim 31 (depends on 30)

The vaccine composition of claim 30, wherein the linker comprises 2-10 linear carbons.

### Claim 32 (depends on 30, 31)

The vaccine composition of claims 30 and 31, wherein the linker is present in the MenA, MenC, MenW-135, or MenY conjugate at a ratio of one linker per 10-100 saccharide repeat units.

### Claim 33 (depends on 30, 31)

The vaccine composition of claims 30 and 31, wherein the linker is present in the MenA, MenC, MenW-135, or MenY conjugate at a ratio of one linker per 20-60 saccharide repeat units.

### Claim 34 (depends on 30, 31)

The vaccine composition of claims 30 and 31, wherein the linker comprises a spacer between a first carbonyl and a second carbonyl, and the spacer comprises 4-8 carbons.

### Claim 35 (depends on 30, 31, 32, 33, 34)

The vaccine composition of any one of claims 30-34, wherein the linker of the MenA conjugate comprises a residue of a dihydrazide.

### Claim 36 (depends on 35)

The vaccine composition of claim 35, wherein the linker of the MenA conjugate comprises a residue of adipic acid dihydrazide.

### Claim 37

The vaccine composition of any one of the preceding claims, wherein the polysaccharide of the MenA, MenC, MenW-135, and/or MenY conjugate is attached to the carrier protein through a linker of formula I:
wherein PS indicates attachment to the polysaccharide and PR indicates attachment to the carrier protein.

### Claim 38 (depends on 30, 31, 32, 33, 34, 35, 36, 37)

The vaccine composition of any one of claims 30-37, wherein the linker is in the MenA conjugate.

### Claim 39 (depends on 30, 31, 32, 33, 34, 35, 36, 37)

The vaccine composition of any one of claims 30-37, wherein the linker is in the MenC conjugate.

### Claim 40 (depends on 30, 31, 32, 33, 34, 35, 36, 37)

The vaccine composition of any one of claims 30-37, wherein the linker is in the MenW-135 conjugate.

### Claim 41 (depends on 30, 31, 32, 33, 34, 35, 36, 37)

The vaccine composition of any one of claims 30-37, wherein the linker is in the MenY conjugate.

### Claim 42

The vaccine composition of any one of the preceding claims, wherein the polysaccharide of the MenA, MenC, MenW-135, and/or MenY conjugate is attached to the carrier protein as shown in formula II:
PR—NH—CH2—PS (II)
wherein PS indicates attachment to the polysaccharide and PR indicates attachment to the carrier protein.

### Claim 43 (depends on 42)

The vaccine composition of claim 42, wherein the polysaccharide of the MenA conjugate is attached to the carrier protein as shown in formula II.

### Claim 44 (depends on 42)

The vaccine composition of claim 42, wherein the polysaccharide of the MenC conjugate is attached to the carrier protein as shown in formula II.

### Claim 45 (depends on 42)

The vaccine composition of claim 42, wherein the polysaccharide of the MenW-135 conjugate is attached to the carrier protein as shown in formula II.

### Claim 46 (depends on 42)

The vaccine composition of claim 42, wherein the polysaccharide of the MenY conjugate is attached to the carrier protein as shown in formula II.

### Claim 47

The vaccine composition of any one of the preceding claims, wherein the carrier protein comprises or consists of recombinant exoprotein A (rEPA), diphtheria toxoid or a B-fragment of diphtheria toxin, CRM197, tetanus toxoid or a C-fragment of tetanus toxin.

### Claim 48

The vaccine composition of any one of the preceding claims, wherein the carrier protein is tetanus toxoid.

### Claim 49

A method of producing a conjugate of a Neisseria meningitidis capsular polysaccharide to a carrier protein, comprising:
a) activating the polysaccharide with an activating agent that can form a carbamate linkage wherein the activating agent is present in a molar excess over the polysaccharide of 20-fold to 50-fold;
b) partially quenching the activated polysaccharide and derivatizing the activated polysaccharide with a dihydrazide linker added at a mole ratio of 0.3 to 1.0 relative to polysaccharide repeat units, wherein the polysaccharide is derivatized at a ratio of one dihydrazide linker per 10-100 saccharide repeat units;
c) conjugating the derivatized polysaccharide to the carrier protein by carbodiimide chemistry, wherein the polysaccharide is present at the beginning of the conjugation reaction at a weight-to-weight ratio of 3:1 to 5:1 relative to the carrier protein, thereby forming the conjugate.

### Claim 50 (depends on 49)

The method of claim 49, wherein the dihydrazide linker is added at a mole ratio of 0.4 to 0.6 relative to polysaccharide repeat units.

### Claim 51 (depends on 49)

The method of claim 49, comprising a further step of quenching the reaction with glycerol.

### Claim 52 (depends on 49, 50, 51)

The method of any one of claims 49 to 51, wherein the dihydrazide linker is adipic acid dihydrazide.

### Claim 53 (depends on 49, 50, 51)

The method of any one of claims 49 to 51, wherein the derivatized polysaccharide is at a starting concentration of 10 g/L to 20 g/L in the conjugation reaction.

### Claim 54 (depends on 49, 50, 51)

The method of any one of claims 49 to 51, wherein the activating agent comprises a carbonyl bound to two N-linked heteroaryls such as CDI (1,1′-Carbonyldiimidazole) and CDT (1,1′-Carbonyl-di-(1,2,4-triazole), or other appropriate leaving groups.

### Claim 55 (depends on 54)

The method of claim 54, wherein the activating agent is carbonyl diimidazole.

### Claim 56 (depends on 49, 50, 51)

The method of any one of claims 49 to 51, wherein the activating agent is present in the activating step in a molar excess over the polysaccharide of 35-fold to 45-fold.

### Claim 57 (depends on 49, 50, 51)

The method of any one of claims 49 to 51, wherein the conjugating step comprises reacting the carrier protein with N-Ethyl-N′-(3-dimethylaminopropyl)carbodiimide.

### Claim 58 (depends on 49, 50, 51)

The method of any one of claims 49 to 51, wherein the polysaccharide is MenA capsular polysaccharide.

### Claim 59 (depends on 49, 50, 51)

The method of any one of claims 49 to 51, wherein the polysaccharide is MenC capsular polysaccharide.

### Claim 60 (depends on 49, 50, 51)

The method of any one of claims 49 to 51, wherein the polysaccharide is MenW-135 or MenY capsular polysaccharide.

### Claim 61

A method of producing a conjugate of a Neisseria meningitidis capsular polysaccharide to a carrier protein, comprising:
a) partially de-O-acetylating the polysaccharide by alkaline hydrolysis;
b) activating the polysaccharide by periodate treatment, thereby converting diols to aldehydes to an extent of at least 20 nmol aldehyde per mg polysaccharide;
c) conjugating the activated polysaccharide to the carrier protein by reductive amination, wherein the polysaccharide is present in the conjugation reaction at a weight-to-weight ratio of 1:1 to 5:1 relative to the carrier protein, thereby forming the conjugate.

### Claim 62 (depends on 61)

The method of claim 61, wherein the polysaccharide is present in the conjugation reaction at a weight-to-weight ratio of 1.5 to 3:1 relative to the carrier protein.

### Claim 63 (depends on 61)

The method of claim 61, wherein the de-O-acetylation reduces the initial amount of O-acetylation in the polysaccharide by 40% to 70%, or 50% to 60%.

### Claim 64 (depends on 61, 62, 63)

The method of any one of claims 61 to 63, wherein following de-O-acetylation, the polysaccharide has a degree of O-acetylation from 0.6 μmol/mg polysaccharide to 1.5 μmol/mg polysaccharide or 0.8 to 1.4 μmol/mg polysaccharide.

### Claim 65 (depends on 64)

The method of claim 64, wherein the degree of O-acetylation is greater than or equal to 0.7, 0.8, 0.9, 1.0, 1.1, or 1.2 μmol/mg polysaccharide.

### Claim 66 (depends on 64)

The method of claim 64, wherein the degree of O-acetylation is less than or equal to 0.8, 0.9, 1.0, 1.1, 1.2, 1.3, or 1.4 μmol/mg polysaccharide.

### Claim 67 (depends on 61, 62, 63, 64, 65, 66)

The method of any one of claims 61 to 66, wherein the activated polysaccharide is at a starting concentration of 20 g/L to 50 g/L in the conjugation reaction.

### Claim 68 (depends on 61, 62, 63, 64, 65, 66)

The method of any one of claims 61 to 66, wherein the polysaccharide is MenC capsular polysaccharide.

### Claim 69 (depends on 61, 62, 63, 64, 65, 66)

The method of any one of claims 61 to 66, wherein the polysaccharide is MenA capsular polysaccharide.

### Claim 70 (depends on 61, 62, 63, 64, 65, 66)

The method of any one of claims 61 to 66, wherein the polysaccharide is MenW-135 or MenY capsular polysaccharide.

### Claim 71 (depends on 61, 62, 63, 64, 65, 66)

The method of any one of claims 61 to 66, wherein the polysaccharide is reduced in size to 30 to 150 kDa or to 50 to 100 kDa before the conjugation reaction.

### Claim 72

A method of producing a conjugate of a Neisseria meningitidis capsular polysaccharide to a carrier protein, comprising:
a) activating the polysaccharide by periodate treatment, thereby converting diols to aldehydes to an extent of at least 50 nmol aldehyde per mg polysaccharide;
b) conjugating the activated polysaccharide to the carrier protein by reductive amination, wherein the polysaccharide is present in the conjugation reaction at a weight-to-weight ratio of 1:1 to 5:1 relative to the carrier protein, thereby forming the conjugate.

### Claim 73 (depends on 72)

The method of claim 72, wherein the polysaccharide is present in the conjugation reaction at a weight-to-weight ratio of 1.5 to 3:1 relative to the carrier protein.

### Claim 74 (depends on 72, 73)

The method of any one of claims 72 and 73, wherein the polysaccharide is MenW-135 or MenY capsular polysaccharide.

### Claim 75 (depends on 72, 73)

The method of any one of claims 72 and 73, wherein the polysaccharide is MenC capsular polysaccharide.

### Claim 76 (depends on 72, 73)

The method of any one of claims 72 and 73, wherein the polysaccharide is MenA capsular polysaccharide.

### Claim 77 (depends on 72, 73, 74, 75, 76)

The method of any one of claims 72 to 76, wherein the polysaccharide is reduced in size to 100 to 200 kDa or to 125 to 175 kDa before the conjugation reaction.

### Claim 78 (depends on 49, 61)

The method of any one of claims 49, 61, and 72, wherein the polysaccharide is reduced in size by acid hydrolysis and/or heat.

### Claim 79 (depends on 49, 61)

The method of any one of claims 49, 61, and 72, wherein the polysaccharide is reduced in size by oxidative cleavage.

### Claim 80 (depends on 72, 73, 74, 75, 76, 77, 78, 79)

The method of any one of claims 72 to 79, wherein reductive amination comprises reducing imines to amines using a cyanoborohydride, or other reducing reagents such as pyridine borane (C5H8BN) and picoline borane complex (C6H7N·BH3).

### Claim 81 (depends on 72, 73, 74, 75, 76, 77, 78, 79)

The method of any one of claims 72 to 79, further comprising converting unreacted aldehydes in the conjugate to alcohols with a reducing reagent.

### Claim 82 (depends on 81)

The method of claim 81, wherein the reducing reagent is a borohydride.

### Claim 83 (depends on 72, 73, 74, 75, 76, 77, 78, 79)

The method of any one of claims 72 to 79, wherein periodate is added to a concentration of 1 mM to 4 mM or 1.5 mM to 3 mM to activate the polysaccharide.

### Claim 84 (depends on 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83)

The method of any one of claims 49 to 83, further comprising purifying the conjugate by hydrophobic interaction chromatography.

### Claim 85 (depends on 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83)

The method of any one of claims 49 to 83, further comprising purifying the conjugate by mixed mode resin chromatography.

### Claim 86

A method of purifying a conjugate of a Neisseria meningitidis capsular polysaccharide to a carrier protein from a mixture containing the conjugate, a salt, and free polysaccharide, comprising:
a) contacting a hydrophobic interaction chromatography resin with the mixture, wherein the conjugate binds the resin;
b) eluting free polysaccharide from the resin; and
c) eluting the conjugate from the resin with an aqueous liquid, wherein the aqueous liquid is free of salt or contains less salt than the mixture, thereby obtaining a composition comprising purified conjugate.

### Claim 87 (depends on 86)

The method of claim 86, wherein the salt comprises ammonium sulfate.

### Claim 88 (depends on 86, 87)

The method of claim 86 or claim 87, wherein the mixture comprises salt in an amount ranging from 0.5 to 1.5 M or 0.8 to 1.2 M.

### Claim 89 (depends on 86, 87, 88)

The method of any one of claims 86 to 88, wherein the aqueous liquid comprises less than 0.2, 0.1, or 0.05 M salt.

### Claim 90 (depends on 86, 87, 88, 89)

The method of any one of claims 86 to 89, wherein the aqueous liquid is water.

### Claim 91 (depends on 86, 87, 88, 89, 90)

The method of any one of claims 86 to 90, wherein the composition comprises less than 20% free polysaccharide by weight, less than 10% free polysaccharide by weight, less than 5% free polysaccharide by weight, or substantially lacks free polysaccharide.

### Claim 92 (depends on 86, 87, 88, 89, 90, 91)

The method of any one of claims 86 to 91, wherein the hydrophobic interaction chromatography resin is a phenyl, propyl, or butyl resin.

### Claim 93 (depends on 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92)

The method of any one of claims 49 to 92, wherein the carrier protein is tetanus toxoid.

### Claim 94 (depends on 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85)

A conjugate produced according to the method of any one of claims 49 to 85.

### Claim 95 (depends on 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85)

A vaccine composition comprising:
a) a first conjugate of MenA capsular polysaccharide to a carrier protein;
b) a second conjugate of MenC capsular polysaccharide to a carrier protein;
c) a third conjugate of MenW-135 capsular polysaccharide to a carrier protein; and
d) a fourth conjugate of MenY capsular polysaccharide to a carrier protein;
wherein one, two, three, or all of the first, second, third, and fourth conjugates was produced according to the method of any one of claims 49 to 85.

### Claim 96 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 95)

The vaccine composition of any one of claims 1-48 or 95, which is free of adjuvant.

### Claim 97 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 95, 96)

The vaccine composition of any one of claims 1-48 or 95-96, further comprising a pharmaceutically acceptable buffer.

### Claim 98 (depends on 97)

The vaccine composition of claim 97, comprising acetate buffer with a pH of 5.5 to 6.5.

### Claim 99 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 95, 96, 97, 98)

The vaccine composition of any one of claims 1-48 or 95-98, further comprising a pharmaceutically acceptable salt.

### Claim 100 (depends on 99)

The vaccine composition of claim 99, wherein the pharmaceutically acceptable salt is sodium chloride.

### Claim 101 (depends on 99, 100)

The vaccine composition of claim 99 or 100, wherein the pharmaceutically acceptable salt is present at 0.45% to 0.9% w/v, or 0.5% w/v to 0.85% w/v.

### Claim 102 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 95, 96, 97, 98, 99, 100, 101)

The vaccine composition of any one of claims 1-48 or 95-101, wherein at least one, two, three, or all four of the first, second, third, and fourth conjugates comprise multiple points of attachment between the polysaccharides and the carrier proteins.

### Claim 103 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 95, 96, 97, 98, 99, 100, 101, 102)

The vaccine composition of any one of claims 1-48 or 95-102, formulated for intramuscular administration.

### Claim 104 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 103, 9495)

A single unit dose of the vaccine composition of any one of claims 1-48 or 9495-103, comprising from 6 μg to 15 μg of each of the MenA, MenC, MenW-135, and MenY polysaccharides.

### Claim 105 (depends on 104)

The single unit dose of claim 104, wherein the carrier protein is present in an amount from 50 μg to 80 μg.

### Claim 106 (depends on 104, 105)

The single unit dose of claim 104 or 105, which is contained in a syringe.

### Claim 107 (depends on 106)

The single unit dose of claim 106, wherein the syringe is silicone-free.

### Claim 108 (depends on 106, 107)

The single unit dose of claim 106 or 107, wherein the syringe is packaged for commercial sale or distribution.

### Claim 109 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 95, 96, 97, 98, 99, 100, 101, 102, 103)

A method of vaccinating a subject against Neisseria meningitidis comprising administering a dose of the vaccine composition of any one of claims 1-48 or 95-103 to the subject.

### Claim 110 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108)

Use of the vaccine composition of any one of claims 1-48 or 95-103 or the single unit dose of any one of claims 104-108 to immunize a subject against Neisseria meningitidis.

### Claim 111 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108)

Use of the vaccine composition of any one of claims 1-48 or 95-103 or the single unit dose of any one of claims 104-108 for the manufacture of a medicament for immunizing a subject against Neisseria meningitidis.

### Claim 112 (depends on 109, 110, 111)

The method or use of any one of claims 109-111, wherein the vaccine is administered intramuscularly.

### Claim 113 (depends on 109, 110, 111, 112)

The method or use of any one of claims 109-112, wherein the subject is age 6 weeks to 3 years.

### Claim 114 (depends on 113)

The method of claim 113, wherein the subject is 2 months, 6 months, 12 months, or 15 months of age.

### Claim 115 (depends on 109, 110, 111, 112)

The method or use of any one of claims 109-112, wherein the subject is age 50 years or more, 55 years or more, 60 years or more, or 65 years or more.

### Claim 116 (depends on 109, 110, 111, 112, 113, 114, 115)

The method or use of any of claims 109-115, wherein the vaccine is administered as a 0.5 mL dose.

### Claim 117 (depends on 116)

The method or use of claim 116, wherein the vaccine comprises 4-10 g each of serogroups A, C, Y, and W-135.

### Claim 118 (depends on 116)

The method or use of claim 116, wherein the vaccine comprises 50-80 g of tetanus toxoid protein.

### Claim 119 (depends on 116)

The method or use of claim 116, wherein the vaccine comprises 4-10 g each of serogroups A, C, Y, and W-135, and 50-80 g of tetanus toxoid protein.

### Claim 120 (depends on 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119)

The method or use of any of claims 109-119, further comprising administering a vaccine that is not directed to Neisseria meningitidis at the same time as, but not in the same injection as, the MenACYW-TT vaccine.

### Claim 121 (depends on 120)

The method or use of claim 120, wherein non-Neisseria meningitidis vaccine is directed to preventing varicella, diphtheria, Hib, hepatitis b, measles, mumps, pertussis, polio, pneumococcus, rotavirus, rubella, or tetanus infections.

### Claim 122 (depends on 120)

The method or use of claim 120, wherein the non-Neisseria meningitidis vaccine is DTaP5, Hib, HepB, DTap5-IPV/Hib, DTap5-IPV/Hib, HepB, MMR, IPV, PCV7, PCV13, RV1 or RV5.

### Claim 123 (depends on 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122)

The method or use of any one of claims 109-122, wherein the subject previously received a Neisseria meningitidis capsular saccharide conjugate vaccine.

### Claim 124 (depends on 123)

The method or use of claim 123, wherein the subject received the Neisseria meningitidis capsular saccharide conjugate vaccine four months to ten years earlier.

### Claim 125 (depends on 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122)

The method or use of any one of claims 109-122, wherein the subject did not previously receive a Neisseria meningitidis capsular saccharide conjugate vaccine.
